Author/Authors :
Miao، نويسنده , , Xiongying and Liu، نويسنده , , Guoxing and Xu، نويسنده , , Xundi and Xie، نويسنده , , Chengzhi and Sun، نويسنده , , Fadi and Yang، نويسنده , , Yaohui and Zhang، نويسنده , , Tao and Hua، نويسنده , , Songwen and Fan، نويسنده , , Wentao and Li، نويسنده , , Qinglong and Huang، نويسنده , , Shengfu and Wang، نويسنده , , Qunwei and Liu، نويسنده , , Guoli and Zhong، نويسنده , , Dewu، نويسنده ,
Abstract :
The vanilloid receptor-1 (VR1) is a ligand-gated, nonselective cation channel expressed predominantly by sensory neurons, but is also involved in carcinogenesis. To elucidate its role in hepatocarcinogenesis, we analyzed the expression of VR1 receptor in tumor and nontumor tissues from human hepatocellular carcinoma (HCC) samples. In situ hybridization analysis showed overexpression of VR1 mRNAs in 9/15 (60.0%) noncancer and 6/15 (40.0%) HCC samples. Immunohistochemistry of 62 HCC samples showed the expression of VR1 increased from normal liver or chronic hepatitis to cirrhosis. Marked expression of VR1 was noted in the majority [31/38 (81.6%)] of cirrhotic liver samples. In HCC, high expression of VR1 was observed in 30/62 (48.4%) cases. Clinicopathologic evaluation indicated a significant correlation between VR1 expression and histopathologic differentiation (P=0.001). Univariate analysis indicated that disease-free survival was significantly better in HCC patients with high versus those with low VR1 expression levels (P= 0.021). Our results indicate that VR1 has anti-HCC progression effects and can be potentially used as a prognostic indicator of HCC. The results suggest the potential beneficiary effects of VR1 expression on the prognosis of patients with HCC.
